Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant
NCT07046910Phase 2Recruiting
- Sponsor
- University of Virginia
- Start
- Apr 2019
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hyperpolarized xenon gas in lung transplant rejection, sponsored by University of Virginia. Primary endpoints: Ventilation Defect Percent at 24 months, Lung gas exchange capacity at 24 months and 2 more. Started Apr 2019; status: recruiting.
02
Drugs
hyperpolarized xenon gas
03
Conditions
lung transplant rejection
Beyond the preview
Go deeper on NCT07046910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046910.